Literature DB >> 7007618

Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.

Y Kamisaki, H Wada, T Yagura, A Matsushima, Y Inada.   

Abstract

Escherichia coli L-asparaginase was modified with monomethoxypolyethylene glycol using cyanuric chloride as a coupler. The modified enzyme did not cross-react with anti-L-asparaginase antibody in precipitin reaction, but retained some catalytic activity (8% of the original activity). It has the same Km value for L-asparagine and the same optimal pH as the native enzyme. The immunogenicity of the modified enzyme was substantially reduced because mouse antiserum to it showed no significant increase in hemagglutinin titer of L-asparaginase-coated sheep red blood cells. After a single i.p. injection of the modified enzyme (80 I.U./kg) into rats, enzyme activity was detected in the serum within 30 min and persisted for over 3 weeks. Concomitant depletion of serum L-asparagine persisted for more than 3 weeks. On the other hand, the active enzyme was rapidly cleared from the serum. The half-lives of the modified and native enzymes were calculated to be 56 and 2.9 hr, respectively. This modified L-asparaginase may be much more useful than the native enzyme for the clinical treatments of tumors because of its reduced immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7007618

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity.

Authors:  O Cohen; C Kronman; T Chitlaru; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

2.  Effect of premedications in a murine model of asparaginase hypersensitivity.

Authors:  Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling
Journal:  J Pharmacol Exp Ther       Date:  2015-01-08       Impact factor: 4.030

3.  The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.

Authors:  Beata Zalewska-Szewczyk; Agnieszka Gach; Krystyna Wyka; Jerzy Bodalski; Wojciech Młynarski
Journal:  Clin Exp Med       Date:  2009-01-30       Impact factor: 3.984

Review 4.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13

6.  Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

Authors:  Y Tsutsumi; T Kihira; S Tsunoda; T Kanamori; S Nakagawa; T Mayumi
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

7.  Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R G Melton; R H Begent
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

8.  Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity.

Authors:  M Chinol; P Casalini; M Maggiolo; S Canevari; E S Omodeo; P Caliceti; F M Veronese; M Cremonesi; F Chiolerio; E Nardone; A G Siccardi; G Paganelli
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

Review 9.  L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.

Authors:  Rachel A Egler; Sanjay P Ahuja; Yousif Matloub
Journal:  J Pharmacol Pharmacother       Date:  2016 Apr-Jun

10.  Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.

Authors:  H Takaku; S Misawa; H Hayashi; K Miyazaki
Journal:  Jpn J Cancer Res       Date:  1993-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.